By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    What Are the Benefits of CBD?
    November 27, 2021
    How to Measure Adult Diapers- The Ultimate Guide to Picking the Right Size
    March 8, 2022
    medicine cabinet
    The Effect Of Finished Dosage Form Manufacturing In New Drugs
    July 5, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Medical Negligence
    The Impact of Medical Negligence: How Claims Can Help You Move Forward
    January 6, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
    PPACA: “It’s in there!”
    September 9, 2017
    Latest News
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Business

Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem, a pharmaceutical company that focuses on stem cell-based technologies, acquired a 51% interest in China-based Suzhou Eyre, which manufactures and develops generic antibiotics and anti-infective drugs, from China Biopharmaceutical Holdings in October 2009.

The sixth line of production, of which there are two more awaiting approval, will push Suzhou Eyre’s product count to nearly 200 drugs. The line is responsible for 20 finished pharmaceutical products, 80% of which are on the China National Insurance Drug List.

More Read

Product Details
Ethical Decisions: Strong Leadership and Effective Planning Are Key
3 Timely Factoids to Make You a Smarter Marketer
Healthcare’s Pricing Cabal
The Priorities of Improving Patient Satisfaction
5% of Patients Account for Half of Health Care Spending

The company’s production lines provided 99% of its $70 million sales in 2010. Its first quarter sales for this year totaled $18 million, a 15% year-over-year increase.

“The Chinese pharmaceutical market, which is the third largest in the world, has estimated sales of over $50 billion for 2011, and is expected to double in the next five years,” said NeoStem CEO Dr. Robin Smith.

According to recent analyst reports, NeoStem, with the assistance of Suzhou Eyre, could see a revenue growth rate of 20% between 2011 and 2013, with the potential to reach $119 million in pharmaceutical sales by 2013.

Indeed, Suzhou Eyre is also in the midst of re-locating to its new 53,000 square foot facility, which it expects will loosen its capacity constraints, improve its productivity and double its capacity.

“Based on the capacity of the new facility, and anticipated volume growth, Erye’s top line revenues should see solid growth in the years ahead and NeoStem’s management will consider our multiple options to realizing the benefits of this increasingly valuable asset,” Smith added.

Aside from its Chinese pharma business, New York-based Neostem has gradually expanded its operations since starting out as a provider of adult stem cell collection and storage services, branching out into cell therapeutics, which is focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US.

Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

As a result of the acquisition, NeoStem can also now develop stem cell therapies in-house, placing it in a solid position for future growth in the field.

With positive results coming out of China today, NeoStem’s stock jumped almost 5% on the AMEX on Monday, trading at $1.47 per share. –Olivia D’Orazio

Source

 

TAGGED:chinahealthcare business
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

car accident lawsuit
Let Your Lawyer Handle the Work Before You Pay Medical Costs
Policy & Law
July 6, 2025
women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025
recovering from injury
Rebuilding After Injury: Path to Physical and Emotional Recovery
News
June 22, 2025

You Might also Like

The Power of Conversations Between Physicians and Patients

March 17, 2014
mobisante ultrasound device
BusinesseHealthMedical DevicesMedical InnovationsTechnology

Interview with Sailesh Chutani, CEO of Mobisante

January 27, 2015

Reconstructive Surgery Is Increasingly Aesthetic

June 6, 2014

A Legal Stimulant is Making People Crazy

July 21, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?